EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review

Catherine-Audrey Boutin, Florence Durocher, Stéphanie Beauchemin, Daniela Ziegler, Claire Nour Abou Chakra, Simon Frédéric Dufresne iD

Clinical Infectious Diseases · 19.07.2024 · 79 (1) · 151-160

DOI: 10.1093/cid/ciae203 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.05.2024. Verfasst von Catherine-Audrey Boutin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Antifungal Agents, Invasive Fungal Infections, Voriconazole, Hematologic Diseases. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AVIR Pharma Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still not fully understood. To help inform clinical decisions, we sought to define microbiological, clinical, and pharmacological characteristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaconazole prophylaxis.

Methods

We performed a systematic review of the literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search strategy was last conducted on 19 April 2023.

Results

We assessed 5293 studies for eligibility, and 300 were selected for data extraction. These studies described 1076 cases of bIFIs occurring under voriconazole (42.5%) or posaconazole (57.5%). The most commonly found pathogens were Aspergillus (40%), Mucorales (20%), Candida (18%), and Fusarium (9%) species. Mucorales were more frequent among voriconazole-emerging cases, whereas Aspergillus and Fusarium were more prevalent among posaconazole-emerging cases. Definitive, putative, or probable antifungal resistance was found in 31% of cases. Therapeutic drug monitoring showed subtherapeutic azole concentration in 32 of 90 (36%) cases. Infection-related mortality was reported in 117 cases and reached 35%.

Conclusions

In our systemic review, the most common bIFIs were aspergillosis, mucormycosis, candidiasis, and fusariosis. Antifungal resistance explains only a minority of cases. Subtherapeutic prophylaxis was frequent but rarely reported. Prospective studies are needed to better understand these infections and to establish optimal management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsInvasive Fungal InfectionsVoriconazoleHematologic DiseasesTriazolesHumansDrug Resistance, FungalAspergillus

Stichwörter der Autor:innen

breakthroughinvasive fungal infectionsposaconazoleprophylaxisvoriconazole

Substanzen

Antifungal AgentsposaconazoleVoriconazoleTriazoles

Autor:innen und Institutionen

  • Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
  • Division of Infectious Diseases, Department of Medicine, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
  • Direction de l'enseignement et de l'Académie, Bibliothèque, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Division of Infectious Diseases and Clinical Microbiology, Department of Medicine, Hôpital Maisonneuve-Rosemont, Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est-de-l'Île-de-Montréal, Montréal, Québ…

ORCID-Profile: Simon Frédéric Dufresne

Förderung

  • AVIR Pharma Inc

Zitieren

APA

Boutin, C. A., Durocher, F., Beauchemin, S., Ziegler, D., Abou Chakra, C. N., & Dufresne, S. F. (2024). Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. Clinical Infectious Diseases, 79(1), 151-160. https://doi.org/10.1093/cid/ciae203

Vancouver

Boutin CA, Durocher F, Beauchemin S, Ziegler D, Abou Chakra CN, Dufresne SF. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. Clinical Infectious Diseases. 2024;79(1):151-160. doi:10.1093/cid/ciae203

BibTeX
@article{Boutin2024,
  author = {Boutin, Catherine-Audrey and Durocher, Florence and Beauchemin, Stéphanie and Ziegler, Daniela and Abou Chakra, Claire Nour and Dufresne, Simon Frédéric},
  title = {Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {1},
  pages = {151--160},
  doi = {10.1093/cid/ciae203}
}
Kostenlos starten →